Preclinical and first-in-human evaluation of AL002, a novel TREM2 agonistic antibody for Alzheimer's disease.
Alzheimer’s disease
Biomarkers
Microglia
Phase 1 clinical trial
TREM2
Journal
Alzheimer's research & therapy
ISSN: 1758-9193
Titre abrégé: Alzheimers Res Ther
Pays: England
ID NLM: 101511643
Informations de publication
Date de publication:
23 Oct 2024
23 Oct 2024
Historique:
received:
26
08
2024
accepted:
09
10
2024
medline:
24
10
2024
pubmed:
24
10
2024
entrez:
24
10
2024
Statut:
epublish
Résumé
Variants of the gene triggering receptor expressed on myeloid cells-2 (TREM2) increase the risk of Alzheimer's disease (AD) and other neurodegenerative disorders. Signaling by TREM2, an innate immune receptor expressed by microglia, is thought to enhance phagocytosis of amyloid beta (Aβ) and other damaged proteins, promote microglial proliferation, migration, and survival, and regulate inflammatory signaling. Thus, TREM2 activation has potential to alter the progression of AD. AL002 is an investigational, engineered, humanized monoclonal immunoglobulin G1 (IgG1) antibody designed to target TREM2. In AD mouse models, an AL002 murine variant has been previously shown to induce microglial proliferation and reduce filamentous Aβ plaques and neurite dystrophy. Preclinical studies assessed the safety, tolerability, pharmacokinetics, and pharmacodynamics of AL002 in cynomolgus monkeys. INVOKE-1 (NCT03635047) was a first-in-human phase 1, randomized, placebo-controlled, double-blind study assessing the safety, tolerability, PK, and PD of AL002 administered as single ascending doses (SAD) in healthy volunteers. In cynomolgus monkeys, weekly intravenous injections of AL002 for 4 weeks were well tolerated, dose-dependently decreased soluble TREM2 (sTREM2) in cerebrospinal fluid (CSF) and total TREM2 in hippocampus and frontal cortex, and increased biomarkers of TREM2 signaling in CSF and brain. In the phase 1 study of 64 healthy volunteers, a single intravenous infusion of AL002 demonstrated brain target engagement based on a dose-dependent reduction of sTREM2 in CSF and parallel increases in biomarkers of TREM2 signaling and microglia recruitment. Single-dose AL002 showed central nervous system penetrance and was well tolerated, with no treatment-related serious adverse events over 12 weeks. These findings support the continued clinical development of AL002 for AD and other neurodegenerative diseases in which TREM2 activation may be beneficial. AL002 is currently being tested in a phase 2, randomized, double-blind, placebo-controlled study in early AD. Clinicaltrials.gov, NCT03635047. Registered on August 15, 2018, https://www. gov/study/NCT03635047 .
Sections du résumé
BACKGROUND
BACKGROUND
Variants of the gene triggering receptor expressed on myeloid cells-2 (TREM2) increase the risk of Alzheimer's disease (AD) and other neurodegenerative disorders. Signaling by TREM2, an innate immune receptor expressed by microglia, is thought to enhance phagocytosis of amyloid beta (Aβ) and other damaged proteins, promote microglial proliferation, migration, and survival, and regulate inflammatory signaling. Thus, TREM2 activation has potential to alter the progression of AD. AL002 is an investigational, engineered, humanized monoclonal immunoglobulin G1 (IgG1) antibody designed to target TREM2. In AD mouse models, an AL002 murine variant has been previously shown to induce microglial proliferation and reduce filamentous Aβ plaques and neurite dystrophy.
METHODS
METHODS
Preclinical studies assessed the safety, tolerability, pharmacokinetics, and pharmacodynamics of AL002 in cynomolgus monkeys. INVOKE-1 (NCT03635047) was a first-in-human phase 1, randomized, placebo-controlled, double-blind study assessing the safety, tolerability, PK, and PD of AL002 administered as single ascending doses (SAD) in healthy volunteers.
RESULTS
RESULTS
In cynomolgus monkeys, weekly intravenous injections of AL002 for 4 weeks were well tolerated, dose-dependently decreased soluble TREM2 (sTREM2) in cerebrospinal fluid (CSF) and total TREM2 in hippocampus and frontal cortex, and increased biomarkers of TREM2 signaling in CSF and brain. In the phase 1 study of 64 healthy volunteers, a single intravenous infusion of AL002 demonstrated brain target engagement based on a dose-dependent reduction of sTREM2 in CSF and parallel increases in biomarkers of TREM2 signaling and microglia recruitment. Single-dose AL002 showed central nervous system penetrance and was well tolerated, with no treatment-related serious adverse events over 12 weeks.
CONCLUSIONS
CONCLUSIONS
These findings support the continued clinical development of AL002 for AD and other neurodegenerative diseases in which TREM2 activation may be beneficial. AL002 is currently being tested in a phase 2, randomized, double-blind, placebo-controlled study in early AD.
TRIAL REGISTRATION
BACKGROUND
Clinicaltrials.gov, NCT03635047. Registered on August 15, 2018, https://www.
CLINICALTRIALS
RESULTS
gov/study/NCT03635047 .
Identifiants
pubmed: 39444037
doi: 10.1186/s13195-024-01599-1
pii: 10.1186/s13195-024-01599-1
doi:
Substances chimiques
Receptors, Immunologic
0
Membrane Glycoproteins
0
TREM2 protein, human
0
Antibodies, Monoclonal, Humanized
0
Banques de données
ClinicalTrials.gov
['NCT03635047']
Types de publication
Journal Article
Randomized Controlled Trial
Clinical Trial, Phase I
Langues
eng
Sous-ensembles de citation
IM
Pagination
235Subventions
Organisme : Alector
ID : N/A
Informations de copyright
© 2024. The Author(s).
Références
Jack CR Jr., Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA Research Framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018;14(4):535–62.
pubmed: 29653606
doi: 10.1016/j.jalz.2018.02.018
Long JM, Holtzman DM. Alzheimer Disease: an update on pathobiology and treatment strategies. Cell. 2019;179(2):312–39.
pubmed: 31564456
pmcid: 6778042
doi: 10.1016/j.cell.2019.09.001
Hanseeuw BJ, Betensky RA, Jacobs HIL, Schultz AP, Sepulcre J, Becker JA, et al. Association of Amyloid and tau with cognition in preclinical Alzheimer Disease: a longitudinal study. JAMA Neurol. 2019;76(8):915–24.
pubmed: 31157827
pmcid: 6547132
doi: 10.1001/jamaneurol.2019.1424
Heneka MT, Golenbock DT, Latz E. Innate immunity in Alzheimer’s disease. Nat Immunol. 2015;16(3):229–36.
pubmed: 25689443
doi: 10.1038/ni.3102
Hou J, Chen Y, Grajales-Reyes G, Colonna M. TREM2 dependent and independent functions of microglia in Alzheimer’s disease. Mol Neurodegener. 2022;17(1):84.
pubmed: 36564824
pmcid: 9783481
doi: 10.1186/s13024-022-00588-y
Szepesi Z, Manouchehrian O, Bachiller S, Deierborg T. Bidirectional microglia-neuron communication in Health and Disease. Front Cell Neurosci. 2018;12:323.
pubmed: 30319362
pmcid: 6170615
doi: 10.3389/fncel.2018.00323
Bellenguez C, Kucukali F, Jansen IE, Kleineidam L, Moreno-Grau S, Amin N, et al. New insights into the genetic etiology of Alzheimer’s disease and related dementias. Nat Genet. 2022;54(4):412–36.
pubmed: 35379992
pmcid: 9005347
doi: 10.1038/s41588-022-01024-z
Schwabe T, Srinivasan K, Rhinn H. Shifting paradigms: the central role of microglia in Alzheimer’s disease. Neurobiol Dis. 2020;143:104962.
pubmed: 32535152
doi: 10.1016/j.nbd.2020.104962
Naj AC, Jun G, Beecham GW, Wang LS, Vardarajan BN, Buros J, et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer’s disease. Nat Genet. 2011;43(5):436–41.
pubmed: 21460841
pmcid: 3090745
doi: 10.1038/ng.801
Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC, Carrasquillo MM, et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer’s disease. Nat Genet. 2011;43(5):429–35.
pubmed: 21460840
pmcid: 3084173
doi: 10.1038/ng.803
Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, et al. TREM2 variants in Alzheimer’s disease. N Engl J Med. 2013;368(2):117–27.
pubmed: 23150934
doi: 10.1056/NEJMoa1211851
Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, et al. Variant of TREM2 associated with the risk of Alzheimer’s disease. N Engl J Med. 2013;368(2):107–16.
pubmed: 23150908
doi: 10.1056/NEJMoa1211103
Jay TR, von Saucken VE, Landreth GE. TREM2 in neurodegenerative diseases. Mol Neurodegener. 2017;12(1):56.
pubmed: 28768545
pmcid: 5541421
doi: 10.1186/s13024-017-0197-5
Rayaprolu S, Mullen B, Baker M, Lynch T, Finger E, Seeley WW, et al. TREM2 in neurodegeneration: evidence for association of the p.R47H variant with frontotemporal dementia and Parkinson’s disease. Mol Neurodegener. 2013;8:19.
pubmed: 23800361
pmcid: 3691612
doi: 10.1186/1750-1326-8-19
Wang Y, Cella M, Mallinson K, Ulrich JD, Young KL, Robinette ML, et al. TREM2 lipid sensing sustains the microglial response in an Alzheimer’s disease model. Cell. 2015;160(6):1061–71.
pubmed: 25728668
pmcid: 4477963
doi: 10.1016/j.cell.2015.01.049
Yeh FL, Wang Y, Tom I, Gonzalez LC, Sheng M. TREM2 binds to Apolipoproteins, including APOE and CLU/APOJ, and thereby facilitates uptake of amyloid-Beta by Microglia. Neuron. 2016;91(2):328–40.
pubmed: 27477018
doi: 10.1016/j.neuron.2016.06.015
Paloneva J, Manninen T, Christman G, Hovanes K, Mandelin J, Adolfsson R, et al. Mutations in two genes encoding different subunits of a receptor signaling complex result in an identical disease phenotype. Am J Hum Genet. 2002;71(3):656–62.
pubmed: 12080485
pmcid: 379202
doi: 10.1086/342259
Cannon JP, O’Driscoll M, Litman GW. Specific lipid recognition is a general feature of CD300 and TREM molecules. Immunogenetics. 2012;64(1):39–47.
pubmed: 21800138
doi: 10.1007/s00251-011-0562-4
Atagi Y, Liu CC, Painter MM, Chen XF, Verbeeck C, Zheng H, et al. Apolipoprotein E is a Ligand for triggering receptor expressed on myeloid cells 2 (TREM2). J Biol Chem. 2015;290(43):26043–50.
pubmed: 26374899
pmcid: 4646257
doi: 10.1074/jbc.M115.679043
Bailey CC, DeVaux LB, Farzan M. The triggering receptor expressed on myeloid cells 2 binds apolipoprotein E. J Biol Chem. 2015;290(43):26033–42.
pubmed: 26374897
pmcid: 4646256
doi: 10.1074/jbc.M115.677286
Zhao Y, Wu X, Li X, Jiang LL, Gui X, Liu Y, et al. TREM2 is a receptor for beta-amyloid that mediates microglial function. Neuron. 2018;97(5):1023–e317.
pubmed: 29518356
pmcid: 5889092
doi: 10.1016/j.neuron.2018.01.031
Gratuze M, Leyns CEG, Holtzman DM. New insights into the role of TREM2 in Alzheimer’s disease. Mol Neurodegener. 2018;13(1):66.
pubmed: 30572908
pmcid: 6302500
doi: 10.1186/s13024-018-0298-9
Yuan P, Condello C, Keene CD, Wang Y, Bird TD, Paul SM, et al. TREM2 haplodeficiency in mice and humans impairs the Microglia barrier function leading to decreased amyloid compaction and severe axonal dystrophy. Neuron. 2016;90(4):724–39.
pubmed: 27196974
pmcid: 4898967
doi: 10.1016/j.neuron.2016.05.003
Jay TR, Hirsch AM, Broihier ML, Miller CM, Neilson LE, Ransohoff RM, et al. Disease Progression-Dependent effects of TREM2 Deficiency in a mouse model of Alzheimer’s Disease. J Neurosci. 2017;37(3):637–47.
pubmed: 28100745
pmcid: 5242410
doi: 10.1523/JNEUROSCI.2110-16.2016
Keren-Shaul H, Spinrad A, Weiner A, Matcovitch-Natan O, Dvir-Szternfeld R, Ulland TK, et al. A Unique Microglia Type Associated with Restricting Development of Alzheimer’s Disease. Cell. 2017;169(7):1276–e9017.
pubmed: 28602351
doi: 10.1016/j.cell.2017.05.018
Jay TR, Miller CM, Cheng PJ, Graham LC, Bemiller S, Broihier ML, et al. TREM2 deficiency eliminates TREM2 + inflammatory macrophages and ameliorates pathology in Alzheimer’s disease mouse models. J Exp Med. 2015;212(3):287–95.
pubmed: 25732305
pmcid: 4354365
doi: 10.1084/jem.20142322
Meilandt WJ, Ngu H, Gogineni A, Lalehzadeh G, Lee SH, Srinivasan K, et al. Trem2 deletion reduces late-stage amyloid Plaque Accumulation, elevates the Abeta42:Abeta40 ratio, and exacerbates axonal dystrophy and dendritic spine loss in the PS2APP Alzheimer’s mouse model. J Neurosci. 2020;40(9):1956–74.
pubmed: 31980586
pmcid: 7046459
doi: 10.1523/JNEUROSCI.1871-19.2019
Wang Y, Ulland TK, Ulrich JD, Song W, Tzaferis JA, Hole JT, et al. TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques. J Exp Med. 2016;213(5):667–75.
pubmed: 27091843
pmcid: 4854736
doi: 10.1084/jem.20151948
Lee CYD, Daggett A, Gu X, Jiang LL, Langfelder P, Li X, et al. Elevated TREM2 gene dosage reprograms Microglia Responsivity and ameliorates pathological phenotypes in Alzheimer’s Disease models. Neuron. 2018;97(5):1032–48. e5.
pubmed: 29518357
pmcid: 5927822
doi: 10.1016/j.neuron.2018.02.002
Schlepckow K, Monroe KM, Kleinberger G, Cantuti-Castelvetri L, Parhizkar S, Xia D, et al. Enhancing protective microglial activities with a dual function TREM2 antibody to the stalk region. EMBO Mol Med. 2020;12(4):e11227.
pubmed: 32154671
pmcid: 7136959
doi: 10.15252/emmm.201911227
Price BR, Sudduth TL, Weekman EM, Johnson S, Hawthorne D, Woolums A, et al. Therapeutic Trem2 activation ameliorates amyloid-beta deposition and improves cognition in the 5XFAD model of amyloid deposition. J Neuroinflammation. 2020;17(1):238.
pubmed: 32795308
pmcid: 7427742
doi: 10.1186/s12974-020-01915-0
Wang S, Mustafa M, Yuede CM, Salazar SV, Kong P, Long H et al. Anti-human TREM2 induces microglia proliferation and reduces pathology in an Alzheimer’s disease model. J Exp Med. 2020;217(9).
Bemiller SM, McCray TJ, Allan K, Formica SV, Xu G, Wilson G, et al. TREM2 deficiency exacerbates tau pathology through dysregulated kinase signaling in a mouse model of tauopathy. Mol Neurodegener. 2017;12(1):74.
pubmed: 29037207
pmcid: 5644120
doi: 10.1186/s13024-017-0216-6
Gratuze M, Leyns CE, Sauerbeck AD, St-Pierre MK, Xiong M, Kim N, et al. Impact of TREM2R47H variant on tau pathology-induced gliosis and neurodegeneration. J Clin Invest. 2020;130(9):4954–68.
pubmed: 32544086
pmcid: 7456230
doi: 10.1172/JCI138179
Leyns CEG, Ulrich JD, Finn MB, Stewart FR, Koscal LJ, Remolina Serrano J, et al. TREM2 deficiency attenuates neuroinflammation and protects against neurodegeneration in a mouse model of tauopathy. Proc Natl Acad Sci U S A. 2017;114(43):11524–9.
pubmed: 29073081
pmcid: 5663386
doi: 10.1073/pnas.1710311114
Sayed FA, Telpoukhovskaia M, Kodama L, Li Y, Zhou Y, Le D, et al. Differential effects of partial and complete loss of TREM2 on microglial injury response and tauopathy. Proc Natl Acad Sci U S A. 2018;115(40):10172–7.
pubmed: 30232263
pmcid: 6176614
doi: 10.1073/pnas.1811411115
Leyns CEG, Gratuze M, Narasimhan S, Jain N, Koscal LJ, Jiang H, et al. TREM2 function impedes tau seeding in neuritic plaques. Nat Neurosci. 2019;22(8):1217–22.
pubmed: 31235932
pmcid: 6660358
doi: 10.1038/s41593-019-0433-0
Gratuze M, Chen Y, Parhizkar S, Jain N, Strickland MR, Serrano JR et al. Activated microglia mitigate Abeta-associated tau seeding and spreading. J Exp Med. 2021;218(8).
Lee SH, Meilandt WJ, Xie L, Gandham VD, Ngu H, Barck KH, et al. Trem2 restrains the enhancement of tau accumulation and neurodegeneration by beta-amyloid pathology. Neuron. 2021;109(8):1283–301. e6.
pubmed: 33675684
doi: 10.1016/j.neuron.2021.02.010
Jain N, Lewis CA, Ulrich JD, Holtzman DM. Chronic TREM2 activation exacerbates Abeta-associated tau seeding and spreading. J Exp Med. 2023;220(1).
Armour KL, Clark MR, Hadley AG, Williamson LM. Recombinant human IgG molecules lacking fcgamma receptor I binding and monocyte triggering activities. Eur J Immunol. 1999;29(8):2613–24.
pubmed: 10458776
doi: 10.1002/(SICI)1521-4141(199908)29:08<2613::AID-IMMU2613>3.0.CO;2-J
de Jong RN, Beurskens FJ, Verploegen S, Strumane K, van Kampen MD, Voorhorst M, et al. A Novel platform for the potentiation of therapeutic antibodies based on Antigen-Dependent formation of IgG hexamers at the cell surface. PLoS Biol. 2016;14(1):e1002344.
pubmed: 26736041
pmcid: 4703389
doi: 10.1371/journal.pbio.1002344
Srinivasan K, Friedman BA, Larson JL, Lauffer BE, Goldstein LD, Appling LL, et al. Untangling the brain’s neuroinflammatory and neurodegenerative transcriptional responses. Nat Commun. 2016;7:11295.
pubmed: 27097852
pmcid: 4844685
doi: 10.1038/ncomms11295
Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association scans. Bioinformatics. 2010;26(17):2190–1.
pubmed: 20616382
pmcid: 2922887
doi: 10.1093/bioinformatics/btq340
Piccio L, Buonsanti C, Cella M, Tassi I, Schmidt RE, Fenoglio C, et al. Identification of soluble TREM-2 in the cerebrospinal fluid and its association with multiple sclerosis and CNS inflammation. Brain. 2008;131(Pt 11):3081–91.
pubmed: 18790823
pmcid: 2577803
doi: 10.1093/brain/awn217
Song WM, Joshita S, Zhou Y, Ulland TK, Gilfillan S, Colonna M. Humanized TREM2 mice reveal microglia-intrinsic and -extrinsic effects of R47H polymorphism. J Exp Med. 2018;215(3):745–60.
pubmed: 29321225
pmcid: 5839761
doi: 10.1084/jem.20171529
Elmore MR, Najafi AR, Koike MA, Dagher NN, Spangenberg EE, Rice RA, et al. Colony-stimulating factor 1 receptor signaling is necessary for microglia viability, unmasking a microglia progenitor cell in the adult brain. Neuron. 2014;82(2):380–97.
pubmed: 24742461
pmcid: 4161285
doi: 10.1016/j.neuron.2014.02.040
Zhao P, Xu Y, Fan X, Li L, Li X, Arase H, et al. Discovery and engineering of an anti-TREM2 antibody to promote amyloid plaque clearance by microglia in 5XFAD mice. MAbs. 2022;14(1):2107971.
pubmed: 35921534
pmcid: 9354770
doi: 10.1080/19420862.2022.2107971
Suarez-Calvet M, Kleinberger G, Araque Caballero MA, Brendel M, Rominger A, Alcolea D, et al. sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer’s disease and associate with neuronal injury markers. EMBO Mol Med. 2016;8(5):466–76.
pubmed: 26941262
pmcid: 5120370
doi: 10.15252/emmm.201506123
Suarez-Calvet M, Araque Caballero MA, Kleinberger G, Bateman RJ, Fagan AM, Morris JC, et al. Early changes in CSF sTREM2 in dominantly inherited Alzheimer’s disease occur after amyloid deposition and neuronal injury. Sci Transl Med. 2016;8(369):369ra178.
pubmed: 27974666
pmcid: 5385711
doi: 10.1126/scitranslmed.aag1767
Piccio L, Deming Y, Del-Aguila JL, Ghezzi L, Holtzman DM, Fagan AM, et al. Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status. Acta Neuropathol. 2016;131(6):925–33.
pubmed: 26754641
pmcid: 4867123
doi: 10.1007/s00401-016-1533-5
Heslegrave A, Heywood W, Paterson R, Magdalinou N, Svensson J, Johansson P, et al. Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer’s disease. Mol Neurodegener. 2016;11:3.
pubmed: 26754172
pmcid: 4709982
doi: 10.1186/s13024-016-0071-x
Chouery E, Delague V, Bergougnoux A, Koussa S, Serre JL, Megarbane A. Mutations in TREM2 lead to pure early-onset dementia without bone cysts. Hum Mutat. 2008;29(9):E194–204.
pubmed: 18546367
doi: 10.1002/humu.20836
Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, et al. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer’s disease mutations: potential factors in amyloid plaque formation. J Neurosci. 2006;26(40):10129–40.
pubmed: 17021169
pmcid: 6674618
doi: 10.1523/JNEUROSCI.1202-06.2006
Gharpure M, Vyavahare S, Ahluwalia P, Gupta SK, Lee TJ, Lohakare J, et al. Alterations in Alzheimer’s disease microglia transcriptome might be involved in bone pathophysiology. Neurobiol Dis. 2024;191:106404.
pubmed: 38184014
doi: 10.1016/j.nbd.2024.106404
Cheng B, Li X, Dai K, Duan S, Rong Z, Chen Y, et al. Triggering receptor expressed on myeloid Cells-2 (TREM2) interacts with colony-stimulating factor 1 receptor (CSF1R) but is not necessary for CSF1/CSF1R-Mediated microglial survival. Front Immunol. 2021;12:633796.
pubmed: 33841415
pmcid: 8027073
doi: 10.3389/fimmu.2021.633796
Griciuc A, Patel S, Federico AN, Choi SH, Innes BJ, Oram MK, et al. TREM2 acts downstream of CD33 in modulating Microglial Pathology in Alzheimer’s Disease. Neuron. 2019;103(5):820–35. e7.
pubmed: 31301936
pmcid: 6728215
doi: 10.1016/j.neuron.2019.06.010
Park SH, Lee EH, Kim HJ, Jo S, Lee S, Seo SW, et al. The relationship of soluble TREM2 to other biomarkers of sporadic Alzheimer’s disease. Sci Rep. 2021;11(1):13050.
pubmed: 34158530
pmcid: 8219697
doi: 10.1038/s41598-021-92101-6